{"title":"Advances in research of histone deacetylase inhibitors in treatment of hematological diseases","authors":"D. Zheng","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.013","DOIUrl":null,"url":null,"abstract":"Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are involved in cell cycle regulation, cell proliferation and survival, cell differentiation, cell metabolism, protein trafficking, DNA repair and angiogenesis. Imbalance of HAT and HDAC is associated with the occurrence of some tumors. Therefore, various targeted drugs targeting the HDAC family may be effective for tumor treatment. This article will review the progress of chidamide, compared with the other histone deacetylase inhibitor (HDACi), in the treatment of hematological diseases such as lymphoma, leukemia, myelodysplastic syndrome (MDS), and multiple myeloma (MM). And these new drugs can serve the clinical practice in a better way. \n \n \nKey words: \nHistone deacetylase inhibitors; Hematologic neoplasms; Molecular targeted therapy; Chidamide; Treatment","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"41 1","pages":"530-534"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are involved in cell cycle regulation, cell proliferation and survival, cell differentiation, cell metabolism, protein trafficking, DNA repair and angiogenesis. Imbalance of HAT and HDAC is associated with the occurrence of some tumors. Therefore, various targeted drugs targeting the HDAC family may be effective for tumor treatment. This article will review the progress of chidamide, compared with the other histone deacetylase inhibitor (HDACi), in the treatment of hematological diseases such as lymphoma, leukemia, myelodysplastic syndrome (MDS), and multiple myeloma (MM). And these new drugs can serve the clinical practice in a better way.
Key words:
Histone deacetylase inhibitors; Hematologic neoplasms; Molecular targeted therapy; Chidamide; Treatment
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
